Drugs / STX-478
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07662798 | Jul → Sep 2026 overdue | — | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06901336 | Mar → May 2025 | — | Scorpion Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05768139 | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX-478 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05768139 ↗ |
| Known as | Tersolisib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07662798 ↗ |
| Action | Inhibit | “STX-478 is a mutant-selective PI3Kα inhibitor” NCT05768139 ↗ |
| Modality | Small molecule | — CHEMBL5421037 ↗ |
| Route | Oral | “oral administration” NCT06901336 ↗ |